A 39-Year Nationwide Study of Uveal Melanoma in Taiwan

IF 2.9 2区医学 Q2 ONCOLOGY

Cancer Medicine Pub Date : 2025-04-15 DOI:10.1002/cam4.70754

An-Ning Chao, Angel Chao, Wei-Yang Chang, Chun-Chieh Wang, Yueh-Ju Tsai, Kuan-Jen Chen, Yih-Shiou Hwang, Lan-Yan Yang

{"title":"A 39-Year Nationwide Study of Uveal Melanoma in Taiwan","authors":"An-Ning Chao, Angel Chao, Wei-Yang Chang, Chun-Chieh Wang, Yueh-Ju Tsai, Kuan-Jen Chen, Yih-Shiou Hwang, Lan-Yan Yang","doi":"10.1002/cam4.70754","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Purpose</h3>\n \n <p>To investigate the incidence, treatment strategies, and survival outcomes of adult patients with uveal melanoma (UM) in Taiwan over a 39-year period.</p>\n </section>\n \n <section>\n \n <h3> Design</h3>\n \n <p>We conducted a retrospective, nationwide population-based cohort study retrieving data from the Taiwan Cancer Registry and the National Death Registry of Health and Welfare Data Science Center database. By employing the International Classification of Diseases diagnostic codes, we identified patients who were diagnosed with UM between January 1980 and December 2018. We analyzed treatment information, as well as mortality data, to gain a comprehensive understanding of the incidence, patient characteristics, treatment patterns, and survival outcomes.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>A total of 314 patients (156 males and 158 females) were diagnosed with UM. The overall incidence rate was 0.36 (range: 0.30–0.42) per million persons, with a mean age at diagnosis of 52 years. In terms of treatment options, enucleation was performed on 122 patients (38.9%), whereas 108 (34.4%) received radiotherapy (RT). The remaining 84 (26.8%) patients underwent alternative treatments. The 5-year overall survival (OS) rate was 58.3%. Pairwise comparisons showed that the OS rates of patients who underwent RT <i>versus</i> surgery were similar. Two factors were associated with favorable OS outcomes: being under 50 years of age (<i>p</i> < 0.001) and being a female (<i>p</i> = 0.04).</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Our real-world study encompassing a 39-year timeframe revealed a relatively low incidence of UM within the Taiwanese population. Patients under the age of 50, as well as females, demonstrated more favorable OS outcomes.</p>\n </section>\n </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 8","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70754","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cam4.70754","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose

To investigate the incidence, treatment strategies, and survival outcomes of adult patients with uveal melanoma (UM) in Taiwan over a 39-year period.

Design

We conducted a retrospective, nationwide population-based cohort study retrieving data from the Taiwan Cancer Registry and the National Death Registry of Health and Welfare Data Science Center database. By employing the International Classification of Diseases diagnostic codes, we identified patients who were diagnosed with UM between January 1980 and December 2018. We analyzed treatment information, as well as mortality data, to gain a comprehensive understanding of the incidence, patient characteristics, treatment patterns, and survival outcomes.

Results

A total of 314 patients (156 males and 158 females) were diagnosed with UM. The overall incidence rate was 0.36 (range: 0.30–0.42) per million persons, with a mean age at diagnosis of 52 years. In terms of treatment options, enucleation was performed on 122 patients (38.9%), whereas 108 (34.4%) received radiotherapy (RT). The remaining 84 (26.8%) patients underwent alternative treatments. The 5-year overall survival (OS) rate was 58.3%. Pairwise comparisons showed that the OS rates of patients who underwent RT versus surgery were similar. Two factors were associated with favorable OS outcomes: being under 50 years of age (p < 0.001) and being a female (p = 0.04).

Conclusions

Our real-world study encompassing a 39-year timeframe revealed a relatively low incidence of UM within the Taiwanese population. Patients under the age of 50, as well as females, demonstrated more favorable OS outcomes.

Abstract Image

查看原文本刊更多论文

目的调查台湾39年来葡萄膜黑色素瘤（UM）成年患者的发病率、治疗策略和生存结果。设计我们从台湾癌症登记处和国家死亡登记处卫生福利数据科学中心的数据库中检索数据，开展了一项以全国人口为基础的回顾性队列研究。通过使用国际疾病分类诊断代码，我们确定了 1980 年 1 月至 2018 年 12 月期间确诊为 UM 的患者。我们分析了治疗信息以及死亡率数据，以全面了解发病率、患者特征、治疗模式和生存结果。结果共有 314 名患者（男性 156 人，女性 158 人）被确诊为 UM。总发病率为 0.36（范围：0.30-0.42）/百万人，平均确诊年龄为 52 岁。在治疗方案方面，122 名患者（38.9%）接受了去核手术，108 名患者（34.4%）接受了放射治疗（RT）。其余 84 名患者（26.8%）接受了其他治疗方法。5年总生存率（OS）为58.3%。配对比较显示，接受 RT 和手术治疗的患者的 OS 率相似。两个因素与良好的 OS 结果相关：50 岁以下（p < 0.001）和女性（p = 0.04）。结论我们的真实世界研究涵盖了 39 年的时间跨度，结果显示台湾人口中 UM 的发病率相对较低。50 岁以下的患者和女性患者的 OS 结果更佳。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Medicine ONCOLOGY-

CiteScore

5.50

自引率

2.50%

发文量

907

审稿时长

19 weeks

期刊介绍： Cancer Medicine is a peer-reviewed, open access, interdisciplinary journal providing rapid publication of research from global biomedical researchers across the cancer sciences. The journal will consider submissions from all oncologic specialties, including, but not limited to, the following areas: Clinical Cancer Research Translational research ∙ clinical trials ∙ chemotherapy ∙ radiation therapy ∙ surgical therapy ∙ clinical observations ∙ clinical guidelines ∙ genetic consultation ∙ ethical considerations Cancer Biology: Molecular biology ∙ cellular biology ∙ molecular genetics ∙ genomics ∙ immunology ∙ epigenetics ∙ metabolic studies ∙ proteomics ∙ cytopathology ∙ carcinogenesis ∙ drug discovery and delivery. Cancer Prevention: Behavioral science ∙ psychosocial studies ∙ screening ∙ nutrition ∙ epidemiology and prevention ∙ community outreach. Bioinformatics: Gene expressions profiles ∙ gene regulation networks ∙ genome bioinformatics ∙ pathwayanalysis ∙ prognostic biomarkers. Cancer Medicine publishes original research articles, systematic reviews, meta-analyses, and research methods papers, along with invited editorials and commentaries. Original research papers must report well-conducted research with conclusions supported by the data presented in the paper.